Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.48 |
| ▸ | CDK2 | P24941 | 3/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.48 |
| ▸ | ATP4A | P20648 | 1/20 | 0.45 |
| ▸ | ATP4B | P51164 | 1/20 | 0.45 |
| ▸ | TDO2 | P48775 | 3/20 | 0.44 |
| ▸ | GSK3B | P49841 | 5/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.43 |
| ▸ | CDK9 | P50750 | 2/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.43 |
| ▸ | CLK1 | P49759 | 2/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30179146 | 1.00 | MEN1 (0.57) | MEN1KMT2ADYRK1ACDK2DYRK1B | |
| SCHEMBL9828569 | 0.78 | HSD17B10 (0.60) | MEN1KMT2ADYRK1ACDK2DYRK1B | |
| SCHEMBL30378846 | 0.78 | HSD17B10 (0.60) | MEN1KMT2ADYRK1ACDK2DYRK1B | |
| SCHEMBL29511166 | 0.78 | MEN1 (0.52) | MEN1KMT2ADYRK1ACDK2DYRK1B | |
| SCHEMBL23175317 | 0.77 | GSK3B (0.71) | MEN1KMT2ADYRK1ACDK2GSK3B | |
| SCHEMBL30554766 | 0.77 | GSK3B (0.56) | MEN1KMT2ADYRK1ACDK2DYRK1B | |
| SCHEMBL21629009 | 0.77 | GSK3B (0.56) | MEN1KMT2ADYRK1ACDK2DYRK1B | |
| SCHEMBL29488164 | 0.77 | GSK3B (0.71) | MEN1KMT2ADYRK1ACDK2GSK3B | |
| SCHEMBL1611705 | 0.73 | CDK5 (0.63) | CDK2ATP4AATP4BGSK3BCDK5 | |
| SCHEMBL1612519 | 0.73 | HTR1A (0.49) | DYRK1ACDK2DYRK1BGSK3BCDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12350265-B2 | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | HANMI PHARM. CO., LTD. (KR) | 2025-07-08 | — | — | US | claimed |
| US-20220354842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | HANMI PHARM. CO., LTD. (KR) | 2022-11-10 | — | — | US | claimed |
| US-20260092051-A1 | PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME | HANMI PHARMACEUTICAL CO LTD (KR) | 2026-04-02 | — | — | US | disclosed |
| US-12433867-B2 | Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia | HANMI PHARM. CO., LTD. (KR) | 2025-10-07 | — | — | US | disclosed |
| US-12350265-B2 | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | HANMI PHARM. CO., LTD. (KR) | 2025-07-08 | — | — | US | disclosed |
| US-12325698-B2 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | HANMI PHARM. CO., LTD. (KR) | 2025-06-10 | — | — | US | disclosed |
| US-20230002358-A1 | PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME | HANMI PHARM. CO., LTD. (KR) | 2023-01-05 | — | — | US | disclosed |
| US-20220354842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | HANMI PHARM. CO., LTD. (KR) | 2022-11-10 | — | — | US | disclosed |
| US-20220110913-A1 | PHARMACEUTICAL COMPOSITION COMPRISING FLT3 INHIBITOR AND HYPOMETHYLATING AGENT FOR TREATING ACUTE MYELOID LEUKEMIA | HANMI PHARM. CO., LTD (KR) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002358-A1 | PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME | DPYD, TYMS, TYMP | MEN1 1082/4885KMT2A 2212/4885DYRK1A 4297/4885 |
| US-20220110913-A1 | PHARMACEUTICAL COMPOSITION COMPRISING FLT3 INHIBITOR AND HYPOMETHYLATING AGENT FOR TREATING ACUTE MYELOID LEUKEMIA | FLT3, MCL1, HGFAC | MEN1 901/4885KMT2A 11/4885DYRK1A 586/4885 |
| US-12325698-B2 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | DPYD, TYMS, TYMP | MEN1 1082/4885KMT2A 2212/4885DYRK1A 4297/4885 |
| US-20220354842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | FLT3, MCL1, CSF3R | MEN1 1801/4885KMT2A 791/4885DYRK1A 1852/4885 |
| US-12350265-B2 | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | FLT3, MCL1, CSF3R | MEN1 1801/4885KMT2A 791/4885DYRK1A 1852/4885 |
| US-12433867-B2 | Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia | FLT3, MCL1, HGFAC | MEN1 901/4885KMT2A 11/4885DYRK1A 586/4885 |
| US-20260092051-A1 | PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME | FLT3, FLT1, ADK | MEN1 4007/4885KMT2A 1769/4885DYRK1A 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.